

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 2004/001209

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A01K 67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPO-INTERNAL, PAJ, BIOSIS, EMBASE, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 0176361 A1 (ELINUS AB), 18 October 2001 (18.10.2001), abstract, page 1, lines 5-14; page 4, lines 6-14; examples 1-6 --	1-9
Y	WO 02057783 A2 (GLAXO GROUP LIMITED), 25 July 2002 (25.07.2002), page 4, line 7 - line 16; page 6, line 15 - line 16; page 7, line 1 - line 13, page 8, line 9 - line 12; page 17, line 29 - page 18, line 12; page 20, line 4 - line 6; examples 2-4, claims 24 and 27-28 --	1-9
Y	Nature, Volume 422, March 13, 2003, Yasuaki Itoh et al, "Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40", page 6928, abstract --	1-9

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

- "&" document member of the same patent family

Date of the actual completion of the international search

17 January 2005

Date of mailing of the international search report

19-01-2005

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. + 46 8 666 02 86

Authorized officer

TERESE PERSSON/BS  
Telephone No. + 46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001209

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>The Journal of Biological Chemistry, Volume 278, No. 13, March 2003, Celia P. Briscoe et al, "The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids", pages 11303-11311</p> <p>--</p>	1-9
P,X	<p>DATABASE WPI Week 200363 Derwent Publication Ltd., London, GB; Class B04, AN 2003-671661 &amp; WO03068959 A1 (TAKEDA CHEM IND LTD), 21 Augusti 2003 (2003-08-21) abstract</p> <p>--</p> <p>-----</p>	1-9

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/SE2004/001209**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - a sequence listing
    - table(s) related to the sequence listing
  - b. format of material
    - in written format
    - in computer readable form
  - c. time of filing/furnishing
    - contained in the international application as filed
    - filed together with the international application in computer readable form
    - furnished subsequently to this Authority for the purposes of search
2.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT  
Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001209

WO	0176361	A1	18/10/2001	AT	247634	T	15/09/2003
				AU	4702201	A	23/10/2001
				AU	6033400	A	31/01/2001
				CA	2414652	A	18/10/2001
				DE	60004675	D,T	17/06/2004
				EP	1196376	A,B	17/04/2002
				SE	1196376	T3	
				EP	1292186	A	19/03/2003
				IL	152135	D	00/00/0000
				JP	2003503382	T	28/01/2003
				JP	2003529379	T	07/10/2003
				SE	0001285	D	00/00/0000
				US	6770679	B	03/08/2004
				US	20030056240	A	20/03/2003
				ZA	200208694	A	19/08/2003

---

WO	02057783	A2	25/07/2002	EP	1354200	A	22/10/2003
				GB	0031527	D	00/00/0000
				US	20040137517	A	15/07/2004

---

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/SE2004/001209

**Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)**

A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GPR 40 under the control of the *Ipfl/Pdx1* promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GPR40, useful for the development of pharmaceuticals towards treatment of the disease.